PO.6.126 Anti-rituximab antibodies demonstrate neutralising capacity, associate with lower circulati...
PO.6.126 Anti-rituximab antibodies demonstrate neutralising capacity, associate with lower circulating drug levels and early relapse in patients undergoing treatment for systemic lupus erythematosus
About this item
Full title
Author / Creator
Wincup, C , Dunn, N , Ruetsch-Chelli, C , Manouchehrinia, A , Kharlamova, N , Naja, M , Seitz-Polski, B , Isenberg, D , Fogdell-Hahn, A , Ciurtin, C and Jury, E
Publisher
London: Lupus Foundation of America
Journal title
Language
English
Formats
Publication information
Publisher
London: Lupus Foundation of America
Subjects
More information
Scope and Contents
Contents
PurposeA major limitation of biologic therapy is formation of anti-drug antibodies (ADA). We have demonstrated ADA to Rituximab (RTX) predict subsequent infusion related reactions. However, little is known regarding the longterm dynamics of ADA to RTX in patients undergoing treatment for SLE. In this study we evaluated the longitudinal impact of AD...
Alternative Titles
Full title
PO.6.126 Anti-rituximab antibodies demonstrate neutralising capacity, associate with lower circulating drug levels and early relapse in patients undergoing treatment for systemic lupus erythematosus
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_f85e751b25794e5883fdfeda97a4a4b8
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_f85e751b25794e5883fdfeda97a4a4b8
Other Identifiers
E-ISSN
2053-8790
DOI
10.1136/lupus-2022-elm2022.147
